J. Rossouw, G. Anderson, R. Prentice, A. Lacroix, C. Kooperberg et al., Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial Evidence from randomised trials on the longterm effects of hormone replacement therapy. Lancet, Jama. Jul, vol.172883603, issue.139337, pp.321-33942, 2002.

E. Oger, M. Canonico, G. Plu-bureau, G. Lowe, P. Scarabin et al., Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk, Thromb Haemost. Bmj. Lancet, vol.83336362, issue.576559382, pp.657-601227, 2000.

V. Marque, M. Alhenc-gelas, G. Plu-bureau, E. Oger, and P. Scarabin, The effects of transdermal and oral estrogen/progesterone regimens on free and total protein S in postmenopausal women Resistance to activated protein C caused by the factor VR506Q mutation is a common risk factor for venous thrombosis, Thromb Haemost. Thromb Haemost, vol.86, issue.2, pp.713-717, 1997.

R. Bertina, B. Koeleman, T. Koster, F. Rosendaal, R. Dirven et al., Mutation in blood coagulation factor V associated with resistance to activated protein C, Nature, vol.369, issue.6475, pp.64-71, 1994.
DOI : 10.1038/369064a0

M. Visser, F. Rosendaal, and R. Bertina, A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis, Blood. Feb, vol.1593, issue.4, pp.1271-1277, 1999.

E. Oger, M. Alhenc-gelas, K. Lacut, M. Blouch, N. Roudaut et al., Differential Effects of Oral and Transdermal Estrogen/Progesterone Regimens on Sensitivity to Activated Protein C Among Postmenopausal Women: A Randomized Trial, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.23, issue.9, pp.1671-1677, 2003.
DOI : 10.1161/01.ATV.0000087141.05044.1F

URL : https://hal.archives-ouvertes.fr/hal-00722263

M. Canonico, E. Oger, G. Plu-bureau, J. Conard, G. Meyer et al., Hormone therapy and venous thromboembolism among postmenopausal women, Maturitas, vol.81, issue.1, pp.840-845, 2007.
DOI : 10.1016/j.maturitas.2015.02.044

URL : https://hal.archives-ouvertes.fr/inserm-01148705

M. Canonico, A. Fournier, L. Carcaillon, V. Olié, G. Plu-bureau et al., Hormone therapy and venous thromboembolism : Early results from the E3N prospective study, 2008.
URL : https://hal.archives-ouvertes.fr/inserm-00289239

C. Straczek, E. Oger, Y. De-jonage-canonico, M. Plu-bureau, G. Conard et al., Prothrombotic Mutations, Hormone Therapy, and Venous Thromboembolism Among Postmenopausal Women: Impact of the Route of Estrogen Administration, Circulation, vol.112, issue.22, pp.3495-500, 2005.
DOI : 10.1161/CIRCULATIONAHA.105.565556

M. Canonico, E. Oger, J. Conard, G. Meyer, H. Levesque et al., Obesity and risk of venous thromboembolism among postmenopausal women: differential impact of hormone therapy by route of estrogen administration. The ESTHER Study, Journal of Thrombosis and Haemostasis, vol.107, issue.6, pp.1259-65, 2006.
DOI : 10.1055/s-2005-871739

URL : https://hal.archives-ouvertes.fr/inserm-00085273

J. Rymer, R. Wilson, and K. Ballard, Making decisions about hormone replacement therapy, BMJ, vol.326, issue.7384, pp.322-328, 2003.
DOI : 10.1136/bmj.326.7384.322

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1125186

W. Utian, D. Archer, G. Bachmann, C. Gallagher, F. Grodstein et al., Estrogen and progestogen use in postmenopausal women position statement of The North American Menopause Society. Menopause, pp.584-602, 2008.

K. Rexrode and J. Manson, Are some types of hormone therapy safer than others? Lessons from the Estrogen and Thromboembolism Risk study. Circulation, Feb, vol.20115, issue.7, pp.820-822, 2007.